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Summary: 
 
Recent developments in the study of the structure and function of opioid receptors raise 
significant challenges for the definition of individual receptor types and the development 
of a nomenclature that precisely describes isoforms that may subserve different functions 
in vivo.  Presentations at the 2013 meeting of the INRC in Cairns, Australia, considered 
some of the new discoveries that are now unraveling the complexities of opioid receptor 
signaling. Variable processing of opioid receptor messenger RNAs may lead to the 
presence of several isoforms of the µ receptor.  Each opioid receptor type can function 
either as a monomer or as part of a homo- or heterodimer or higher multimer. 
Additionally, recent evidence points to the existence of agonist bias in the signal 
transduction pathways activated through µ receptors, and to the presence of regulatory 
allosteric sites on the receptors.  This brief review summarizes the recent discoveries that 
raise challenges for receptor definition and the characterization of signal transduction 
pathways activated by specific receptor forms.  
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Almost two decades ago, the International Union of Pharmacology (IUPHAR) 
established a nomenclature committee to standardize the definitions and characterize the 
properties of receptors activated by neurotransmitters, hormones, cytokines and many 
drugs - this committee is known by the acronym NC-IUPHAR.  In turn NC-IUPHAR 
established subcommittees to make recommendations on specific receptors and to 
develop a database defining the receptor systems and drug targets coded by the human 
genome with references to the most appropriate experimental models and the best 
selective radioligands, agonists and antagonists. This database can be found at 
http://www.iuphar-db.org; it is a mine of useful information for almost all receptors and 
ion channels.  
 
The well-established Greek symbol terminology, µ,, and , for the first three types of 
opioid receptors to be identified, was proposed by Bill Martin, Hans Kosterlitz and their 
co-workers (Martin et al, 1976; Gilbert et al, 1976; Lord et al, 1977) in the mid-1970s. In 
1996, an alternative terminology was proposed by an NC-IUPHAR subcommittee 
(Dhawan et al, 1996) but this terminology was not accepted by the field and is no longer 
used.  A reconstituted Opioid Receptor Nomenclature Subcommittee (ORNS) proposed a 
return to the original nomenclature for opioid receptors, and added additional 
recommendations relating to the opioid receptor family and the receptor that is selectively 
activated by the endogenous ligand, nociceptin/orphanin FQ (abbreviated here as 
N/OFQ).  The recommended revised terminology and abbreviations were accepted by 
NC-IUPHAR, and can be found on the NC-IUPHAR website:  http://www.iuphar-
db.org/DATABASE/FamilyIntroductionForward?familyId=50.   The recommended 
nomenclature is briefly summarized in Table 1. 
 
The close structural homologies between the three classic types of opioid receptors, µ, , 
and , and the more recently discovered receptor for N/OFQ have been confirmed by the 
recent reports of the crystal structures of each of these receptors when complexed with 
antagonists (Manglik et al, 2012; Granier et al, 2012; Wu et al, 2012; Thompson et al, 
2012).  They are clearly members of one family of proteins, with the differences between 
the receptor types arising by gene duplication events during evolution. It is thus 
appropriate to group these receptors as a single receptor family.  NC-IUPHAR policy is 
to name receptors after their endogenous ligands, and to require that the abbreviation 
selected to represent a receptor family is two letters when there would be potential for 
confusion with other receptors if a single letter were to be used. Given the existence of 
receptors for oxytocin (OT) and orexins (OX), the family name selected by NC-IUPHAR 
for opioid receptors is OP (i.e., Opioid Peptide receptors).  The Greek symbol 
terminology for the three receptors of the opioid receptor family that were first 
discovered, µ, , and , is retained, so these become the µ receptor, the  receptor and the 
 receptor (or µOP receptor, OP receptor, and OP receptor). Since it is sometimes 
inconvenient or impractical to use the Greek symbols, alternative abbreviations 
recognized by NC-IUPHAR are MOP receptor, DOP receptor, and KOP receptor.  By 
analogy, the fourth member of the family becomes the NOP receptor (for nociceptin 
opioid peptide receptor).  Note that in the NC-IUPHAR system the letter R for receptor is A
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never used as part of the receptor name since this adds no information to the terminology; 
the context usually makes clear that the terminology refers to a receptor. The widely used 
abbreviations MOR, DOR and KOR are therefore inconsistent with the NC-IUPHAR 
standards for receptor nomenclature; the ORNS recommends that these abbreviations 
should not be used to describe opioid receptor types.  A summary of the recommended 
nomenclature and abbreviations for opioid receptors types is presented in Table 1.  
 
Some investigators have questioned whether the NOP receptor should be classified as a 
member of the opioid receptor family, perhaps influenced by Hans Kosterlitz’ dictum, 
frequently repeated by him at INRC meetings during the 1970s and 1980s, that if a 
receptor mediated action is not antagonized by naloxone, then the action should not be 
called an opioid receptor mediated effect. This insistence on a rigid procedural definition 
of an "opioid" was valuable at the time.  For example, it became apparent that the actions 
of drugs at the sigma receptor, originally identified by Bill Martin as an opioid receptor 
(Martin et al, 1976; Gilbert et al, 1976), were not antagonized by naloxone (in contrast to 
Martin’s original claim) and should not be called opioid.  Subsequent studies have 
established that the sigma receptor exists, but as a protein that is very different in 
structure and function from the µ,, and  receptors (Seth et al, 1998). Furthermore, 
many of the ligands that activate this receptor have very different structures from the 
endogenous ligands for the opioid receptors (Hayashi & Su, 2005). Kosterlitz' dictum 
need not be applied to the entire OP receptor family.  The NOP receptor, unlike sigma 
receptors, is very similar in structure and in most functions to the other OP receptors.  
Actions of N/OFQ through the NOP are not antagonized by naloxone, but the amino acid 
sequence of N/OFQ indicates that this peptide is closely related structurally to the 
endogenous opioid peptides, probably derived during evolution by gene duplications 
among the opioid peptide gene family in much the same way as the various OP receptor 
forms diverged by gene duplication during evolution (Nothacker et al, 1996). As noted 
above, the NOP receptor crystal structure closely resembles the crystal structures of the 
µ, , and  receptors and is more similar to these than to other GPCRs. Thus, in contrast 
to sigma receptors, NOP receptors display primary, secondary and tertiary structural 
similarity to other members of the OP receptor family, and are activated by an 
endogenous ligand that has a primary structure that is closely related to that of the 
endogenous ligands for the µ, , and  receptors.  Additionally, the NOP receptor 
employs a repertoire of signal transduction pathways that is very similar to the set of 
pathways activated by the three classic opioid receptors.  These structural and functional 
considerations trump the absence of sensitivity to naloxone antagonism and clearly 
necessitate the assignment of the NOP receptors to the OP receptor family. The NOP 
receptor should be considered a subcategory of the OP receptor family with 
atypical low affinity for the classic opioid peptides (the enkephalins, -endorphin 
and dynorphin) and insensitivity to antagonism by naloxone. 
 
Several issues that have implications for opioid receptor classification and nomenclature 
were discussed during the 2013 INRC meeting.  An area with potential significance for 
OP receptor classification is the growing evidence that the signal transduction pathways 
that are activated by agonists acting at the same receptor type are not always identical.  
Evidence that individual agonist ligands may preferentially direct the functional response A
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elicited by their common receptor to different transduction pathways was the subject of a 
plenary lecture by Arthur Christopoulos on biased agonism at GPCRs.  The main 
emphasis of Christopoulos' talk was on other GPCRs, not specifically on opioid 
receptors, but other speakers addressed biased agonism at OP receptors. Eamonn Kelly 
from Bristol showed unambiguously that certain agonists at MOP receptors bias the 
response towards either G protein- or -arrestin-mediated transduction pathways.  The 
signaling pathway repertoire that can be activated by these transducers is also expanding. 
For example, Wendy Walwyn presented evidence that  and NOP receptors can activate 
cofilin, an actin-modulating protein, via -arrestin, ROCK and LIMK.  Until recently it 
had been assumed that any ligand that could activate a receptor would induce essentially 
the same cellular response, with the major differences in response relating to the relative 
efficacies of different agonists.  Now that biased agonism at OP receptors is an 
established fact, apparent differences in the responses induced by agonists that act at the 
same receptor type do not require the postulation of separate receptor sub-types for each 
agonist; the same receptor may be differentially biased by each agonist to mediate 
different transduction pathways.  
 
Functional studies of OP receptors in the 1980 and 1990s suggested the existence of 
subtypes of the major OP receptor forms; specifically differences in the relative potencies 
of selected agonists at  receptors and their differential sensitivities to certain antagonists 
led to claims of the existence of subtypes of  receptor (see review by Zaki et al, 1996).  
At µ receptors, the actions of some agonists are reported to be more readily antagonized 
by the irreversible antagonist, naloxonazine, than others (Pasternak & Wood, 1988; Paul 
et al, 1989). These observations led to the proposal that there are subclasses of  and µ 
receptor, named 1, 2, µ1 and µ2, but no evidence for the existence of more than one gene 
for the -or µ receptors exists despite careful homology searches of the genome. Knock-
out of the  receptor gene is reported to abolish the activity of ligands preferentially 
acting at both 1 and 2 sites (Filliol et al, 2000). There are also proposals for the 
existence of subtypes of  receptor, based on relative agonist potencies for selected 
actions that appear to be mediated byreceptors (Rothman et al, 1989). However, a 
triple knockout of µ, , and  receptors completely abolishes binding and function of all 
opioid ligands (Clark et al., 2002; Martin et al, 2003), indicating that these ligands require 
at least one of the three receptor members of the OP receptor family for activity.  
 
It is possible that some or all of the data leading to the proposal that there are subtypes of 
µ, , and  receptors might be explained by biased agonism. Agonist potency ratios are 
now only interpretable if the experimental system from which the data is obtained is fully 
defined, including not only the receptor type mediating the actions, but also the cell 
type(s), experimental conditions and the signal transduction systems mediating the 
measured effects.  Examining differences in the relative potencies of a series of agonists 
in different cell or tissue preparations or in vivo was historically an important approach to 
the identification of heterogeneity of many receptor types.  It was this type of evidence 
that was used in part to support the proposed  receptor subtypes (Zaki et al., 1996). 
However, because of the possibility of biased agonism, differential agonist potency or 
efficacy can no longer be regarded as strong enough evidence to postulate the existence A
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of non-identical receptors as the mediators of these actions, although antagonist 
dissociation constants continue to provide more robust evidence of receptor 
heterogeneity. These conclusions have significance for the receptor databases. Agonist 
potency ratios are of value in the context of highly defined experimental systems but 
must be interpreted with caution. The possible existence of opioid receptor subtypes 
should be reexamined in the light of recent studies demonstrating biased agonism at 
opioid receptors 
 
Apparent receptor heterogeneity might also be induced by interactions of receptors with 
interacting proteins or modulating ligands. In 1997, Cvejic & Devi and her colleagues 
reported that OP receptors could form homodimers, and in 1999 they showed the 
formation of functional heterodimers with ligand binding properties that differed from 
those displayed by either of the individual receptor types (Jordan & Devi, 1999). In the 
case of the  receptor heterodimer, the ligand binding properties were found to match 
the properties of the putative 2 subtype (Zukin et al., 1988).  Subsequently many other 
groups have confirmed the existence of opioid receptor dimers and higher-order forms 
(oligomers), and the observation has been extended to many other GPCRs (Milligan, 
2009).  Indeed, several non-opioid GPCRs, including chemokine and serotonin receptors 
have now been reported to form functional heterodimers with opioid receptors (Hebert 
2008; Cussac et al, 2012; Rozenfeld and Devi, 2010). But to date it has not been 
unambiguously demonstrated that the reported µ, , and  receptor heterogeneity can be 
accounted for by receptor heterodimerization.  Towards this end, reagents that allow 
detection and evaluation of the endogenous OP heterodimers are being generated and 
these have begun to show promising results; heterodimer-selective antibodies have 
been useful in revealing morphine-induced upregulation of this heterodimer in the brain 
and in demonstrating heterodimer-directed signal trafficking (Rozenfeld & Devi, 2007). 
Ligands selectively targeting the heterodimer have helped demonstrate allosteric 
modulation of ligand binding and signaling by heterodimerization (Gomes et al, 2011; 
2013) as well as the exploration of the pharmacological properties of heterodimers in vivo 
(Daniels et al, 2005; Milan-Lobo, et al, 2013). Finally, cell-permeable peptides that 
selectively disrupt the heterodimer have helped address the contribution of this 
heterodimer to opioid pharmacology (He et al, 2011).  Reagents such as these will be 
valuable in addressing the extent to which receptor heterogeneity could be attributed to 
opioid receptors heterodimers in biological systems. 
 
Agonist actions at many GPCRs are additionally subject to either positive or negative 
regulation by ligands acting through allosteric regulatory sites on the GPCR.  The 
existence of allosteric modulators of the µ receptor (Burford et al., 2013) was discussed 
at the meeting by Andrew Alt and John Traynor.  Positive and negative allosteric 
compounds binding to a GPCR change receptor conformation to either enhance or inhibit 
orthosteric agonist binding and receptor activation; positive allosteric modulators may 
also show agonist effects, such compounds are allosteric agonists. A key finding is that 
the allosteric modulator-occupied receptor can have differential affinity for some, but not 
all orthosteric ligands, resulting in probe dependence; moreover, the allosteric modulator 
may induce, or change the direction of, signaling bias. Thus differential sensitivity of the 
activation of receptors by diverse agonists to allosteric regulation offers another potential A
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explanation for the apparent differences in the actions of different agonists at the same 
receptor. These observations point to the need for additional research describing more 
completely allosteric modulatory sites on each OP receptor. Because there are changes in 
relative agonist affinity and/or efficacy, and perhaps induction of a signaling bias, the 
allosteric modulator-bound receptor may be considered a novel entity. On the other hand 
allosteric modulators only subtly alter receptor conformation and so an OP receptor 
bound to an allosteric modulator remains an OP receptor, based on the structural and 
functional arguments discussed earlier. Nonetheless, the fact that allosteric modulators 
can differentially change the ability of agonists to bind to and activate the receptor and 
may have agonist actions on their own presents new challenges for OP receptor 
nomenclature, and in particular for opioid ligand nomenclature.  
 
The role of alternative transcription from a single gene as a potential basis for OP 
receptor subtypes is also controversial.  Gavril Pasternak and others have shown that 
there is more than one transcription start site on the µ receptor gene and multiple 
alternative mRNA splicing pathways, resulting in multiple transcripts coding for proteins 
with different primary structures (Abbadie et al, 2000; Koch et al, 2001; Kvam et al, 
2004).  It is suggested that these variant receptor forms can account for the apparent 
functional heterogeneity of µ receptors (Pasternak & Pan, 2013) There are no reports of 
multiple start sites and alternative transcripts for the  and receptor genes. Thus, the 
alternative transcript hypothesis is only plausible as a potential explanation for the 
apparent heterogeneity of µ receptors but, with few exceptions (e.g. Liu et al., 2011), 
there remains much uncertainty about the levels of expression of the variant mRNA 
forms for this receptor, their stability in the cell, and the properties of any proteins 
expressed from these mRNA variants. The presence of functional receptor proteins 
derived from variant transcripts (arising from different transcription start sites or 
alternative mRNA splicing) from a single receptor gene requires further study. If 
confirmed then a consistent nomenclature differentiating the variant forms of a single 
receptor will need to be developed.  
 
Sequence variations within opioid receptor genes might cause the expressed receptors to 
display properties that distinguish these receptors from those of the most frequently 
expressed receptor form. There are numerous single nucleotide polymorphisms (SNPs) in 
human opioid receptor genes, but most are rare and none are known to alter the 
conformations of the expressed receptor (Mague & Blendy, 2010). Only one 
polymorphism in the coding region of human opioid receptor genes is known to occur 
with relatively high frequency (rs 1799971; varying from 40 to 50% is some Asian 
populations to 5% or less in African Americans: Gelernter et al, 1999) and its known 
functional consequences are limited. A change of adenosine to guanosine in position 118 
(A118G) of the coding region (exon 1) of the human µ opioid receptor gene results in the 
expression of a receptor with aspartic acid (Asp) in position 40 instead of asparagine  
(Asn); this change removes a potential glycosylation site. A transgenic mouse line in 
which guanosine is replaced by adenosine in the equivalent position of the mouse µ 
receptor gene (A112G, expressing N38D) resulted in expression of receptors with similar 
ligand binding properties but reduced levels of expression of the receptor mRNA and 
reduced receptor protein levels relative to the wild-type receptor (Mague & Blendy, A
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2009).  This is consistent with other reports that downstream signaling is impaired in the 
variant form relative to the wild-type human µ receptor (Mague & Blendy ,2010; Oertel 
et l 2012). The mechanism for the reduced level of expression may relate to increases in 
methylation of the 118G µ receptor gene.  Oertel et al (2012) report that the degree of 
gene methylation at positions +117 and adjacent downstream methylation sites was 
higher in heroin-using subjects expressing the 118G variant than in 118A expressing 
subjects. In 118G subjects, chronic heroin use was not associated with elevated levels of 
µ receptor expression, but in 118A subjects chronic heroin use induced an upregulation 
of µ receptor expression in the thalamus and a cortical region. Increased receptor 
methylation in the 118G receptor gene may impede receptor up-regulation in response the 
drug exposure, suggesting an epigenetic regulation of the level of expression of µ 
receptors (Oertel et al, 2012).  This work requires confirmation in a larger set of subjects.  
To date however, there are no reports indicating that functional opioid receptors with 
altered ligand binding or signal transduction properties are produced as a result of 
polymorphisms in opioid receptor genes.  
 
Some opioid drugs have been reported to bind to non-opioid receptor proteins such as 
filamin A which interacts directly with µ receptors (Wang HY et al. 2008), or to the toll-
like receptor-4 (TLR-4) (Hutchinson et al., 2011) that does not interact directly with 
opioid receptors. Naturally, the structural requirements for interaction of opioids with 
these proteins are very different from their binding to classical opioid receptors. 
Nonetheless the interactions might be important, e.g., direct actions of opioids on the 
TLR-4 complex have been proposed to activate microglia to mediate many of the adverse 
effects of morphine (Hutchinson et al., 2011). However, this potential mechanism has 
been ruled out in other studies of morphine-induced microglial activation (Ferrini et al., 
2013; Fukugawa et al., 2013) and the affinity of interaction of opioids with TLR-4 
mechanisms is at least several orders of magnitude weaker than their interaction with 
MOPr (Wang et al., 2012), questioning their pharmacological relevance. Thus the 
functional relevance of binding of some opioid drugs to proteins other than the opioid 
receptors is not clearly established.  Since these interactions do not involve direct binding 
to opioid receptors, it is not feasible to define them within the framework of an opioid 
receptor nomenclature, but investigators need to be aware that ligands for opioid 
receptors, like many other receptor ligands, can interact with other proteins with possible 
functional consequences, whether with very high affinity as for filamin A (Wang HY et 
al, 2008) or with low affinity as for TLR4 (Wang X et al, 2012).  
 
 
Concluding comments:    
There has been a growing consensus on use of the recommended opioid receptor 
nomenclature shown in Table 1 since publication of the most recent NC-IUPHAR 
recommendation. If and until the accepted nomenclature for opioid receptors is revised to 
encompass the proposed variant forms of µ, , and  receptors based on more stringent 
criteria that take into account the additional variables in receptor properties outlined 
above, we suggest that the simple classification in Table 1 be used by all authors. 
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Beyond μ, δ, κ and NOP receptors, a description of opioid receptor subtypes such as μ1 or 
μ2 is not recommended unless they are described as putative. We do not consider that the 
evidence for opioid receptors subtypes that has been offered to date provides 
unambiguous evidence of independent functional receptors that are not variant forms of 
the major opioid receptors.  Until a new nomenclature for opioid receptor variants 
encompassing possible alternative transcription start sites or splice sites, receptor homo- 
and hetero-multimers, positive and negative allosteric regulation, and biased agonism is 
established and accepted by the research community, any such proposed variants should 
be fully described. Evidence of activation of signaling pathway(s) not previously 
associated with opioid receptors, the identification of novel allosteric regulatory site(s), 
and the establishment of novel polymeric structures should not be considered sufficient 
justification for modification of the current nomenclature.  
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Table 1.  NC-IUPHAR Approved Nomenclature for Opioid Peptide Receptors 
 
Receptors activated by opiate drugs respond physiologically to endogenous opioid 
peptides; they are therefore Opioid Peptide receptors, the receptor family being 
designated by the two-letter abbreviation OP. 
 
 
Current NC-IUPHAR  Other (non-approved)  Presumed Endogenous 
Approved Nomenclature
1
 Nomenclature   Ligand(s) 
________________________________________________________________________ 
 
µ, mu, or MOP  MOR, OP3   -endorphin (not selective3) 
        enkephalins (not selective
3
) 
        endomorphin-1
2
 
        endomorphin-2
2
 
 
 delta, or DOP  DOR, OP1   enkephalins (not selective3) 
        -endorphin (not selective3) 
 
, kappa, or KOP  KOR, OP2   dynorphin A 
        dynorphin B 
        -neoendorphin 
 
NOP    ORL1, OP4   nociceptin/orphanin FQ  
        (N/OFQ) 
________________________________________________________________________ 
 
Footnotes: 
1. The well-established Greek terminology for opioid receptor types using the descriptors 
µ, , and  is recommended, but where Greek symbols are not permitted or impractical, 
the use of mu, delta or kappa, or MOP, DOP, or KOP is permissible. 
 
2. No mechanism for the endogenous synthesis of endormorphins has been identified; 
their status as endogenous ligands for the µ receptor is tentative.  
 
3. "Not selective" indicates that these ligands are not strongly selective for the specific 
receptor types indicated; they may have sufficient affinity and efficacy at other opioid 
receptors to exert pharmacological effects through the non-preferred site. For example, 
the enkephalins are listed as non-selective ligands for both µ and receptors.  However, 
all ligands in this table have very low affinity and efficacy at non-opioid GPCRs.  
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Table of Abbreviations: 
 
DOP,  receptor, a member of the OP receptor family 
GPCR, G-protein coupled receptor 
INRC, International Narcotics Research Conference 
IUPHAR, International Union of Basic and Clinical Pharmacology 
KOP,  receptor, a member of the OP receptor family 
LIMK, Lim domain kinase 
MOP, µ receptor, a member of the OP receptor family 
NC-IUPHAR, International Union of Basic and Clinical Pharmacology Receptor 
Nomenclature Committee 
N/OFQ, nociception/orphanin FQ 
NOP, N/OFQ receptor, a member of the OP receptor family 
ORNS, Opioid Receptor Nomenclature Subcommittee 
OP, NC-IUPHAR abbreviation for opioid receptor family 
ROCK, Rho-associated protein kinase 
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